Related Experiment Video
Updated: Jun 16, 2026
In vitro Quantitative Imaging Assay for Phagocytosis of Dead Neuroblastoma Cells by iPSC-Macrophages
Published on: February 14, 2021
Intracellular bevacizumab reduces phagocytotic uptake in RPE cells
Alexa Klettner1, Friederike Möhle, Johann Roider
1Department of Ophthalmology, University of Kiel,, Arnold-Heller-Str. 3, Haus 25, 24105, Kiel, Germany. aklettner@auge.uni-kiel.de
Background:
We have previously shown that bevacizumab, but not ranibizumab, is taken up by porcine RPE cells. In this study, the effects of bevacizumab and ranibizumab on proliferation, wound healing and phagocytosis of the RPE were investigated.
Methods:
Primary porcine RPE cell culture were prepared from fresh eyes, cultivated and treated with clinically relevant concentrations of bevacizumab or ranibizumab respectively. Proliferation was investigated in a proliferation assay, wound healing in a wound scratch assay and phagocytosis was investigated by feeding RPE cells photoreceptor outer segment-opsonized FITC-labeled latex beads.
Results:
Bevacizumab, and to a lesser extend ranibizumab, impair the proliferation of RPE cells but do not affect wound healing. Bevacizumab, but not ranibizumab, reduces the phagocytotic function of RPE cells.
Conclusions:
The uptake of bevacizumab reduces phagocytosis in RPE cells, which indicates possible long-term effects of repeated bevacizumab treatment.
